Wenqi Jiang

机构：Guiyang Medical University, Chinese Academy of Sciences, Shanghai Institute of Materia Medica · ORCID：0000-0002-4302-9861

发表论文 79 篇 · 总被引 1701 次 · h-index 17

代表论文

• Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial (2019 · The Lancet Haematology · 被引 250)
• A phase II study of sintilimab, anlotinib, and pegaspargase sandwiched with radiotherapy as first‐line therapy in patients with newly diagnosed, stage I–II extranodal natural‐killer/T‐cell lymphoma (2023 · American Journal of Hematology · 被引 24)
• The dual role of CD70 in B‐cell lymphomagenesis (2022 · Clinical and Translational Medicine · 被引 21)
• Distinct clinical and genetic features of hepatitis B virus–associated follicular lymphoma in Chinese patients (2022 · Blood Advances · 被引 20)
• Expression of PD-L1 on Monocytes Is a Novel Predictor of Prognosis in Natural Killer/T-Cell Lymphoma (2020 · Frontiers in Oncology · 被引 16)
• Clinical Outcome of an Multicentre, Randomized, Phase II Clinical Trial for Patients with Extranodal NK/T Cell Lymphoma Treated By P-Gemox or Aspametdex (2019 · Blood · 被引 16)